In last trading session, MaxCyte Inc (NASDAQ:MXCT) saw 0.88 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.30 trading at $0.07 or 3.14% at ring of the bell on the day assigns it a market valuation of $244.53M. That closing price of MXCT’s stock is at a discount of -128.7% from its 52-week high price of $5.26 and is indicating a premium of 8.7% from its 52-week low price of $2.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.22 million shares which gives us an average trading volume of 761.63K if we extend that period to 3-months.
For MaxCyte Inc (MXCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
MaxCyte Inc (NASDAQ:MXCT) trade information
Upright in the green during last session for gaining 3.14%, in the last five days MXCT remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $2.30 price level, adding 6.88% to its value on the day. MaxCyte Inc’s shares saw a change of -44.71% in year-to-date performance and have moved -2.34% in past 5-day. MaxCyte Inc (NASDAQ:MXCT) showed a performance of -9.80% in past 30-days. Number of shares sold short was 3.54 million shares which calculate 5.2 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 61.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -160.87% in reaching the projected high whereas dropping to the targeted low would mean a loss of -160.87% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.37% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 8.33% while estimates for its earnings growth in next 5 years are of 9.40%.
MaxCyte Inc (NASDAQ:MXCT)’s Major holders
Insiders are in possession of 1.23% of company’s total shares while institution are holding 76.05 percent of that, with stock having share float percentage of 77.00%. Investors also watch the number of corporate investors in a company very closely, which is 76.05% institutions for MaxCyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at MXCT for having 8.14 million shares of worth $31.92 million. And as of 2024-06-30, it was holding 7.7814 of the company’s outstanding shares.
The second largest institutional holder is CADIAN CAPITAL MANAGEMENT, LP, which was holding about 7.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.285 of outstanding shares, having a total worth of $29.88 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.81 shares of worth $6.47 million or 2.64% of the total outstanding shares. The later fund manager was in possession of 2.77 shares on Mar 31, 2025 , making its stake of worth around $6.37 million in the company or a holder of 2.60% of company’s stock.
